IMU-838 could be alternative treatment option for RRMS patients who are ineligible with MAbs
Click HERE to Subscribe for the MS Beacon Newsletter Following the publication of positive top-line data from the Phase II EMPhASIS…
A Lancet study update: Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis
Having MS does not bar you from getting COVID-19. This is the reason why we we post articles concerning this…
Stuart Schlossman
Management of Multiple Sclerosis in the Era of COVID-19: Recommendations and Guidance from Penn Neurosciences – Penn Medicine
If you think you have been exposed to COVID‑19 and develop a fever and symptoms, such as cough or difficulty…
Stuart Schlossman
Drugs in Development for MS, Including Ofatumumab (with MS Neurology experts Lublin; Bar-Or; Calabresi; Coyle and Krieger)
This NeurologyLive Peer Exchange, “Advances in Early Treatment Approaches in Multiple Sclerosis,” includes insight from Fred D. Lublin, MD; Amit Bar-Or, MD, FRCP;…
Stuart Schlossman
Targeting Bruton Tyrosine Kinase for Multiple Sclerosis Treatment
An in-depth look into the expanding landscape of multiple sclerosis treatments that target bruton tyrosine kinase. By: Jennifer S. Sun,…
Stuart Schlossman
Boosting Cellular Energy at Sites of Myelin Loss May Stop MS Progression
COVID-19 alert If you think you have been exposed to COVID‑19 and develop a fever and symptoms, such as cough…
Stuart Schlossman
COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
Stay Healthy, Stay Home and Wash Your Hands Click HERE to Subscribe for the MS Beacon Newsletter ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Despite a…
Stuart Schlossman
Favorable outcomes reported for COVID-19 patients with MS on Teriflunomide
If you think you have been exposed to COVID‑19 and develop a fever and symptoms, such as cough or difficulty…
Stuart Schlossman
The Gut Microbiota and Risk of Relapse in MS
If you think you have been exposed to COVID‑19 and develop a fever and symptoms, such as cough or difficulty…
Stuart Schlossman
Treating the Whole Patient: Incorporating Behavioral Medicine into MS Management
Amy Sullivan, PsyD, Director of Behavioral Medicine at the Mellen Center for Multiple Sclerosis at Cleveland Clinic, described the benefits…
Stuart Schlossman
